Physician profile
Eric G Levy
NPI 1891779021
$2,996.88
in general payments reported to CMS, 2019-2025
23 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $274 · 2021: $310 · 2022: $11.71 · 2023: $563 · 2024: $578 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $727.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $483.70 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $233.24 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.41 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $182.23 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $179.96 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.14 | 2023-2025 | |
| Abbvie INC. | $134.70 | 2021-2023 | |
| Angiodynamics, INC. | $103.75 | 2025 | Nanoknife |
| Exact Sciences Corporation | $87.58 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $65.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.03 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $51.59 | 2019-2021 | |
| Mylan Specialty L.P. | $50.95 | 2019-2024 | Yupelri |
| Amgen INC. | $49.82 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $49.73 | 2020-2021 | |
| Sanofi Pasteur INC. | $34.83 | 2019 | |
| Amarin Pharma, INC. | $34.00 | 2019-2020 | |
| Genzyme Corporation | $27.04 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $26.97 | 2021-2024 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $19.46 | 2021 | |
| Neurocrine Biosciences, INC. | $19.08 | 2019 | |
| Allergan, INC. | $15.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.